m‐TOR inhibitors and their potential role in haematological malignancies
- 1 February 2017
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 177 (5), 684-702
- https://doi.org/10.1111/bjh.14529
Abstract
It is widely demonstrated that the PI3K-AKT-mTOR signalling is critical in normal myeloid and lymphoid development and function. Thus, it is not strange that this pathway is often deregulated in haematological tumours, providing a strong preclinical rationale for the use of drugs targeting the PI3K-AKT-mTOR axis in haematological malignancies. The main focus of this review is to examine the mammalian target of rapamycin (mTOR, also termed mechanistic target of rapamycin [MTOR]) signalling pathways and to provide a brief overview of rapalogs and second-generation mTOR inhibitors used to target its aberrant activation in cancer treatment. We will also discuss the results obtained with the use of these agents in patients with acute leukaemia, Hodgkin lymphoma, non-Hodgkin lymphomas, multiple myeloma and Waldenström macroglobulinaemia. Ongoing clinical trials in haematological malignancies that are investigating first- and second-generation mTOR inhibitors as single agents and as components of combination regimens are also presented.Keywords
This publication has 117 references indexed in Scilit:
- Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo studyBMC Cancer, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology, 2011
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaLeukemia, 2010
- The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationCancer, 2010
- mTOR and cancer: many loops in one pathwayCurrent Opinion in Cell Biology, 2009
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008
- Rapamycin and mTOR kinase inhibitorsJournal of Chemical Biology, 2008
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature, 2003